Munjal S, et al. - The efficacy and safety of DFN-15 (an oral liquid formulation of celecoxib) in adults with migraine were investigated. Furthermore, the researchers evaluated variability in patient-identified most bothersome symptom (MBS) across 3 migraine attacks. For the 2-hour pain-free endpoint, both doses of DFN-15 outperformed placebo, but the differences were not statistically significant due to a carryover effect with placebo. DFN-15 120 mg was being further developed for the management of acute migraine as the response to both doses was similar.